Navigation Links
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
Date:7/1/2011

has been shown to safely and effectively help keep people from developing preventable blood clots," said Alan Brownstein, Chief Executive Officer of the National Blood Clot Alliance. "The FDA approval of a new blood thinner, XARELTO®, offers a new option for patients seeking knee or hip replacement surgery, and we encourage people to discuss with their physicians the risk of blood clots and which blood thinner offers optimal protection as part of their pre-surgical consultation."

Pivotal data from the XARELTO® Phase 3 clinical development program reflected in the approved label showed significantly greater efficacy of rivaroxaban, both in head-to-head comparison with enoxaparin and when comparing extended-duration (5 weeks) rivaroxaban with short-duration (2 weeks) enoxaparin, followed by placebo. In these trials, rivaroxaban and enoxaparin demonstrated similar safety profiles including low rates of major bleeding.

XARELTO® is approved for use at a 10 mg dose, once-daily for 35 days following hip replacement and for 12 days following knee replacement surgery. To date, XARELTO® is approved in more than 110 countries worldwide and has been successfully launched in more than 80 countries by Bayer HealthCare. Janssen Pharmaceuticals, Inc. holds marketing rights for XARELTO® in the U.S. The U.S. Bayer HealthCare sales force will support the Janssen Pharmaceuticals, Inc. sales force by detailing XARELTO® in designated hospital accounts.

"Shorter hospital stays following hip and knee replacement surgeries have made the prevention of venous blood clots an outpatient issue, and XARELTO® provides a safe and effective oral treatment option that can be easily transitioned from use in hospital to home," said Paul Chang, M.D., Vice President, Medical Affairs, Internal Medicine, Janssen Pharmaceuticals, Inc. "We're pleased to make XARELTO® tablets available to physicians to help them better protect their patient
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. FDA Approves Nulojix for Kidney Transplant Patients
4. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
5. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
6. FDA Approves Redesigned Labels for Some Merck Drugs
7. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
8. FDA Approves Marketing of RMS Subcutaneous Needle Sets
9. FDA Approves Injectable Gel to Treat Fecal Incontinence
10. FDA approves Incivek for hepatitis C
11. FDA Approves Sutent for Rare Type of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, asthma ... of Yujiro S. Hata to its board ... in business and corporate development is a tremendous asset ... president and chief executive officer of Xencor. "Xencor faces ...
(Date:7/30/2015)... COLUMBUS, Ohio, July 30, 2015 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... in the quarter. , Net earnings per diluted ... in the prior-year period. Adjusted EPS was $2.80 , ...
(Date:7/30/2015)... July 30, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin ... non-exclusive Development Agreements with Dexcom, Inc. to allow ... with the Dexcom G5 and G6 continuous glucose ... generation pump platform with Dexcom,s future CGM systems ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... Requests Enhancements to Risk Mitigation Strategies Consistent with ... ... (Nasdaq:,CEPH) announced today receipt of a complete response letter from ... Application,(sNDA) for FENTORA(R) (fentanyl buccal tablet) [C-II] as a treatment ...
... Theranostics Health (TH) today,announced that it has ... the,Federal Government. This, along with its Medical ... of Health & Mental Hygiene, allows the ... the,disciplines/specialties of Immunology/protein microarray and,Pathology/histopathology., The ...
Cached Medicine Technology:Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain 2Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain 3Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain 4Theranostics Health Receives Green Light to Perform Clinical Testing 2
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the innovative ... for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is a ... understand the benefits of using medication management technologies . , ...
(Date:7/31/2015)... ... July 31, 2015 , ... ZH Healthcare announces a new cloud based service ... Health IT as a Service (HITaaS) is a Healthcare dedicated cloud based service that ... , HITaaS manages all aspects of infrastructure, security, runtime, middleware, OS, virtualization, ...
(Date:7/31/2015)... ... ... Physical therapy for knee osteoarthritis is an important part of knee pain ... from doing what they want or need to do. The patient may have trouble getting ... patient's exercise regime may be limited by the pain in their knee. When a patient ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers invites the public to ... August 15th, 2015 from 9am – 12pm. Timber frame raisings are special, ... entire community as the culmination of months of effort, planning, fundraising, and dreaming takes ...
(Date:7/31/2015)... ... ... The Radiology Business Management Association’s 2015 Fall Educational Conference ... Care: A View From Capitol Hill” on Sunday, Sept. 27, 2015, in Austin, Tex. ... has a special understanding of the real world impact of health care policy issues,” ...
Breaking Medicine News(10 mins):Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3
... food safety lawyer, writes about why it is essential for ... says that there is a major defect in the food ... inhibits people affected or even killed by contaminated food products ... level, it prevents our society from knowing the source of ...
... adults, which is the most common type of myotonic dystrophy ... the University of Virginia Health System have shown for the ... acid) in muscle cells could result in the reversing myotonic ... the United States have myotonic muscular dystrophy (MMD). The disease ...
... first trimester could be associated with cardiac abnormalities in ... septal defects, Journal Birth Defects Research Part B, Trimester, ... who take non-steroidal anti-inflammatory drugs (NSAIDs) early in their ... babies with congenital defects. ,The findings of ...
... children who are highly sensitive to allergies in the first ... asthma. // ,Sabina Illi and colleagues at the University ... of exposure to allergens in early life and the effect ... function and asthma. They had reported their findings in the ...
... say that a commonly used HIV drug may be useful ... be used in prevention of the cancer and could be ... and his colleagues said that such a cream could prove ... lesions. However no clinical trials have begun as yet. ...
... Another 14 people have succumbed to an outbreak of mosquito-borne ... These deaths are in addition to the 26 people already ... around 437 people have been infected with the disease and ... more than what were detected in the first six months ...
Cached Medicine News:Health News:Importance of knowing the source of our food 2Health News:Toxic Strand Of RNA Causes Myotonic Muscular dystrophy 2Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Babies Prone To Allergies More likely To Be Asthmatic 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: